X4 Pharmaceuticals (XFOR) Invested Capital (2017 - 2025)

X4 Pharmaceuticals has reported Invested Capital for 9 years, with the latest figure at $261.3 million in Q4 2025.

• For the quarter ending Q4 2025, Invested Capital rose 168.96% year-over-year to $261.3 million; the trailing twelve-month figure through Dec 2025 stood at $261.3 million (up 168.96% YoY), and the FY2025 full-year result was $261.3 million, up 168.96% from the prior year.
• Invested Capital for Q4 2025 stood at $261.3 million, up from $136.6 million in the prior quarter.
• The five-year high for Invested Capital was $261.3 million in Q4 2025, with the low at $56.0 million in Q1 2024.
• Historically, Invested Capital has averaged $112.3 million across 5 years, with a median of $100.6 million in 2021.
• The largest YoY upside for Invested Capital was 168.96% in 2025 against a maximum downside of 53.4% in 2025.
• X4 Pharmaceuticals' Invested Capital stood at $96.9 million in 2021, then rose by 9.95% to $106.6 million in 2022, then declined by 0.42% to $106.1 million in 2023, then retreated by 8.44% to $97.1 million in 2024, then jumped by 168.96% to $261.3 million in 2025.
• The last three Invested Capital figures came in at $261.3 million (Q4 2025), $136.6 million (Q3 2025), and $79.0 million (Q2 2025), per Business Quant data.